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Transcatheter mitral valve repair with the MitraClip, a catheter-based percutaneous edge-to-edge repair technique to correct mitral regurgitation 
(MR), has been demonstrated in Western studies to be an effective and safe MR treatment strategy. However, randomised clinical trial data 
on its use in Asian-Pacific patients is limited. Hence, the Asian Pacific Society of Cardiology convened an expert panel to review the available 
literature on MitraClip and to develop consensus recommendations to guide clinicians in the region. The panel developed statements on the 
use of MitraClip for the management of degenerative MR, functional MR, and other less common indications, such as acute MR, dynamic MR, 
hypertrophic obstructive cardiomyopathy, and MR after failed surgical repair. Each statement was voted on by each panel member and consensus 
was reached when 80% of experts voted ‘agree’ or ‘neutral’. This consensus-building process resulted in 10 consensus recommendations to 
guide general cardiologists in the evaluation and management of patients in whom MitraClip treatment is being contemplated.
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Transmitral valve repair can be performed with the MitraClip, a catheter-
based percutaneous edge-to-edge repair technique to correct mitral 
regurgitation (MR), by connecting the anterior and the posterior leaflet of 
a regurgitant mitral valve. Data from the EVEREST II high-risk registry, as 
well as Asian registry data, demonstrate that the MitraClip procedure is 
feasible and safe.1–3 
MitraClip was also evaluated in MITRA-FR and COAPT. Both these 
randomised controlled trials included patients with heart failure (New York 
Heart Association [NYHA] functional class ≥2 despite optimal guideline-
directed medical therapy [GDMT]), reduced ejection fraction, and 
moderate-to-severe or severe secondary MR who received medical 
treatment with or without MitraClip implantation. The MITRA-FR trial did 
not show a significant difference in the composite primary endpoint of 
death from any cause and unplanned hospitalisation for heart failure at 
12 months (54.6% in the device group versus 51.3% in the medical group; 
p=0.53).4 In contrast, the COAPT trial showed that the primary endpoint of 
all hospitalisations for heart failure within 24 months was significantly 
lower in the device group than in the control group (35.8% versus 67.9%, 
p<0.001).5 The 2020 American College of Cardiology/American Heart 
Association guideline for the management of patients with valvular heart 
disease recommends the MitraClip in treating severely symptomatic 
patients with primary MR who are at high or prohibitive surgical risk.6
In Asia-Pacific, MitraClip has been reserved for patients who are at high or 
prohibitive surgical risk, although many Asian patients with intermediate 
or low surgical risk still refuse to undergo surgery.3 For these patients, the 
MitraClip may be a reasonable treatment option. However, published data 
on the use of the MitraClip among Asian populations are limited compared 
with the West.7 The multicentre retrospective MARS registry, involving 
eight sites in five Asia-Pacific countries, reported the early experience in 
Asia with 142 patients who underwent the MitraClip procedure from 
February 2011 to October 2013. In this study, the acute procedural success 
rate was 93.7%.2 
Given the limited published clinical evidence on the use of MitraClip in the 
Asia-Pacific region, the Asian Pacific Society of Cardiology (APSC) 
developed these consensus recommendations to provide expert 
guidance on the potential role of MitraClip in the treatment of MR in the 
region. These consensus recommendations are intended to guide general 
cardiologists and internists practicing cardiology in managing MR and 
evaluating patient suitability for MitraClip repair. However, the consensus 
recommendations are not intended to replace clinical judgement.
Methods
The APSC convened a 26-member panel to review the literature on the 
use of MitraClip in the management of MR, discuss gaps in the current 
management strategies, outline areas where further guidance is needed 
and, ultimately, develop consensus recommendations on the use of 
MitraClip. The experts were mostly members of the APSC who were 
nominated by national societies and endorsed by the APSC consensus 
board, as well as international experts in the MitraClip procedure. For 
these consensus recommendations, the expert panel decided to adapt 
the echocardiographic criteria from the American Society of 
Echocardiography guidelines, with a focus on parameters identifying 
severe MR patients suitable for MitraClip use (Figure 1), as the common 
definition for discussions during the consensus meeting.8
A comprehensive literature search was conducted, with particular focus 
on Asian-centric studies. Selected applicable articles were reviewed and 
appraised using the Grading of Recommendations Assessment, 
Development, and Evaluation system as follows:
1. High (authors have high confidence that the true effect is similar to 
the estimated effect).
2. Moderate (authors believe that the true effect is probably close to the 
estimated effect).
3. Low (true effect might be markedly different from the estimated 
effect). 
4. Very low (true effect is probably markedly different from the 
estimated effect).9 
The evidence was then discussed in two consensus meetings, held on 18 
January 2020 and 27 June 2020.
Consensus recommendations for the use of MitraClip in the management 
of degenerative mitral regurgitation (DMR), functional mitral regurgitation 
(FMR), and other less common indications in the Asia-Pacific setting were 
developed during the two meetings. The statements were each put to an 
online vote using a three-point scale (agree, neutral, or disagree). 
Consensus was reached when 80% of experts voted agree or neutral. 
When there was not consensus, the statements were further discussed 
via email then revised accordingly until the criteria for consensus were 
reached.
MitraClip Use in Degenerative 
Mitral Regurgitation
Statement 1. Both symptomatic and asymptomatic patients with ≥3+ 
DMR, who meet the indications for surgery but are considered high 
risk by the Heart Team, should be considered for MitraClip 
implantation.
Level of evidence: Moderate.
Level of agreement: 80% agree, 16% neutral, 4% disagree.
Statement 2. MitraClip use should be considered for symptomatic 
high-risk ≥3+ DMR patients with or without reduced left ventricular 
ejection fraction (LVEF).
Level of evidence: Moderate.
Level of agreement: 84% agree, 12% neutral, 4% disagree.
Statement 3. MitraClip use should be considered for asymptomatic 
patients with high-risk ≥3+ DMR, with:
• Reduced LVEF and/or LV dilatation; or
• New onset AF or pulmonary hypertension.
Level of evidence: Low.
Level of consensus: 84% agree, 16% neutral, 0% disagree.
 
DMR, wherein one of the components of the mitral apparatus (leaflets, 
chords or papillary muscles) is affected, is often the result of degenerative 
mitral valve disease characterised by morphological changes in the 
connective tissue of the valve over time and resulting in MR.10,11 DMR may 
be either the result of fibroelastic deficiency or due to diffuse myxomatous 
disease.12,13 It may present across a spectrum ranging from isolated 
prolapse of a single leaflet scallop to bileaflet prolapse and annular 
dilation.10 
Surgical mitral valve repair or replacement is still the gold standard for 
DMR, although transcatheter therapy may have a role in the management 
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of a subset of patients.7,8,14,15 Data from MARS found that the acute 
procedural success rate for patients with DMR was 92%.3 The 30-day 
major adverse event rate was 14.7%, which was not significantly different 
from FMR patients (9.2%; p=0.555). Both FMR and DMR patients had 
significant improvements in the severity of MR and NYHA functional class 
after 30 days. There was a significantly greater reduction in LV end-
diastolic diameter (p=0.002) and end-systolic diameter (p=0.017) in DMR 
than in FMR. 
In addition, the AVJ-514 trial also provided Asian evidence to support the 
use of MitraClip in DMR patients. AVJ-514 was a prospective, multicentre, 
single-arm study that included patients with symptomatic chronic 
moderate-to-severe (3+) or severe (4+) DMR (n=16) or FMR (n=14). Among 
DMR patients, the acute procedural success rate was 87.5% and 81.3% 
had MR grade ≤2+ at 30 days.16 The proportion of patients with NYHA 
functional class III/IV was reduced from 37.5% to 6.3%. No deaths were 
reported.
The panel agreed to recommend MitraClip for high-risk patients with 
symptomatic severe DMR with or without reduced LVEF; high-risk 
asymptomatic patients with severe DMR with reduced LVEF and LV 
dilatation; and those with new-onset AF or pulmonary hypertension, who 
meet the indications for surgery but are considered high risk by the Heart 
Team. However, some panellists underscored the absence of clinical data 
in asymptomatic patients, which then lowered the level of evidence for 
this subgroup. One dissenting opinion for Statement 1 explained that only 
asymptomatic patients with prohibitively high risk should be considered 
for MitraClip therapy. For Statement 2, one dissenting opinion explained 
that such patients should be considered for surgery first, and MitraClip 
should be limited to those with high surgical risk.  
While some experts stated their preference to treat early prior to 
deterioration or severe LV remodelling, the overall panel opinion was that 
there was no reason to intervene in asymptomatic patients with severe 
DMR with good LVEF and no LV dilatation (except those with new-onset AF 
EROA = effective regurgitant orifice area; LA = left atrium; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; PASP = pulmonary artery systolic pressure; 
RF = regurgitant fraction; Rvol = regurgitant volume.
Figure 1: Schematic Illustration of Echocardiographic Parameters for Mitral Regurgitation Assessment 
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or pulmonary hypertension). These patients should continue to be 
observed closely.
MitraClip Use in Functional Mitral Regurgitation
Statement 4. MitraClip should be considered for (≥3+) symptomatic 
FMR patients who are already on GDMT. FMR patients should receive 
at least 1 month of optimised GDMT, with reasonable attempts to 
uptitrate treatment, as well as cardiac resynchronisation therapy 
defibrillator (CRT-D) if indicated, before being evaluated for further 
intervention or MitraClip use.
Level of evidence: High.
Level of consensus: 88% agree, 8% neutral, 4% disagree.
Statement 5. For patients with ischaemic FMR (≥3+), coronary 
anatomy, ischaemia evaluation and potential revascularisation should 
be performed before MitraClip consideration. If the coronary 
revascularisation strategy is percutaneous coronary intervention, 
staged MitraClip should be considered. If the coronary revascularisation 
strategy is coronary artery bypass graft (CABG), concomitant surgical 
mitral valve repair/replacement may be considered.
Level of evidence: Low.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Statement 6. FMR patients should be monitored regularly (e.g. every 
6 months) and referred early to the Heart Team (including a MitraClip 
specialist, heart failure specialist, echocardiologist and surgeon) for 
intervention, including MitraClip implantation. Discussions and 
endorsements of futility should be deferred to the Heart Team.
Level of evidence: Low.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Statement 7. Symptomatic patients with ≥3+ FMR should be 
assessed by the Heart Team for possible MitraClip implantation.
Level of evidence: High.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Statement 8. FMR patients who do not meet the eligibility criteria for 
MitraClip implantation (e.g. asymptomatic patients, those with MR 
severity of ≤2+, and those with less-optimised GDMT) should be 
closely monitored. These patients should be considered for MitraClip 
implantation once the eligibility criteria are met.
Level of evidence: Low.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
In FMR, the components of the mitral apparatus remain intact but there is 
resultant MR because of dysfunctional coaptation of the leaflets, usually 
as a result of ventricular or annular dilation.11 Patients with functional MR 
usually have LV dysfunction and most of them undergo medical treatment 
for the treatment of underlying conditions such as hypertension, 
dyslipidaemia, AF, coronary artery disease and heart failure. Guidelines 
recommend that these conditions be adequately treated – including the 
use of CRT-D when indicated – together with the management of the MR.14 
Among those with FMR in Asia, 66% have an ischaemic aetiology.3 Hence, 
ischaemic evaluation is a crucial step in patient assessment. Coronary 
angiography is the preferred method of ischaemia assessment although 
the use of CT coronary angiography and other modalities would be 
acceptable in selected patients. Correctable ischaemia should be 
adequately treated (i.e. revascularisation and medical therapy); MitraClip 
may then be considered for severe symptomatic residual FMR (≥3+).
As first suggested by the EVEREST II trial, MitraClip is a suitable alternative 
treatment option for symptomatic FMR patients.1 The definitive COAPT 
trial also showed that patients with moderate-to-severe (grade 3+) or 
severe (grade 4+) secondary MR had a significantly lower rate of all 
hospitalisations for heart failure (primary endpoint) within 24 months with 
MitraClip compared with controls (35.8% versus 67.9%; p<0.001).5 All-
cause mortality was also significantly lower in the device group (29.1% 
versus 46.1%; p<0.001). The secondary endpoints of quality of life, 
functional capacity, MR grade and LV remodelling also favoured MitraClip 
over controls. 
The MITRA-FR trial did not show a significant difference in the composite 
primary endpoint of death from any cause and unplanned hospitalisation 
for heart failure at 12 months.4 On cursory examination, both the COAPT 
and MITRA-FR studies examined similar cohorts of FMR patients. However, 
there are several key differences in patient selection that have been 
instructive in the appropriate selection of the MitraClip and would also 
explain the differences between the two study outcomes. Firstly, the 
COAPT study is arguably a more robust study with a central inclusion 
committee, larger (almost double) sample size, detailed follow-up with 
echocardiography and functional studies (e.g. 6-minute walk test) and a 
requirement for stable doses of GDMT prior to enrolment, compared to 
the MITRA-FR. In addition, the COAPT study reported superior technical 
success rates and lower complication rates than the MITRA-FR study. 
Thirdly the criteria for MR severity also differed between COAPT and 
MITRA-FR, with the COAPT adopting more stringent criteria to qualify for 
severe MR. Finally, and perhaps most importantly, the COAPT study 
selected patients who had disproportionately severe MR compared to 
MITRA-FR patients who appeared to have more proportionate MR. The 
concept of disproportionate MR, first described by Grayburn et al. is 
beyond the scope of this paper, but in brief, refers to a situation where the 
MR is more severe relative to the LV volume.17 This implies a mechanical 
dysfunction of the mitral valve driving a significant element of the 
underlying heart failure.
According to the ACCESS-EU registry, which included patients with 
significant MR (77% of whom had FMR), there was an improvement in the 
severity of MR at 12 months compared with baseline (p<0.0001), with 
78.9% of patients free from MR of >2+ severity at 12 months.18 The 
6-minute-walk-test improved by 59.5 ± 112.4 m and the 1-year survival rate 
was 81.8%. The MARS registry also reported that the acute procedural 
success rates of MitraClip for FMR was 95.5%.3 Among the 14 patients in 
the AVJ-514 trial with FMR, acute procedural success rate was 85.7% and 
92.9% of patients had MR grade ≤2+ after 30 days. The proportion of 
patients with NYHA functional class III/IV was reduced from 35.7%  to 
0.0%.16 No deaths were reported. 
For patients with FMR, the panel recommended that MitraClip may be 
considered as long as medical therapy has already been dose-optimised 
for at least 1 month and, if appropriate, have had a CRT-D implanted. While 
a few panellists recommend observing on GDMT for up to 3 months, data 
from COAPT suggest that patients with more severe disease should 
probably not wait unnecessarily. 
FMR patients who are potential candidates for MitraClip therapy should 
be monitored regularly by the general cardiologist via echocardiography, 
then referred to the Heart Team (MitraClip specialist, heart failure 
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specialist, echocardiologist and surgeon) as soon as the patient fits the 
eligibility criteria (i.e. symptomatic moderate-to-severe FMR). All patients 
with LV dysfunction should undergo close surveillance.
The panel recommends the use of transoesophageal echocardiogram 
(TOE) to define MR aetiology while transthoracic echocardiogram (TTE) 
would be more appropriate for severity assessment as TOE may be 
influenced by haemodynamic variables during sedation. TOE may be used 
alone only for instances where the use of TTE is challenging.
Surgical risk should be considered by the Heart Team when deciding on 
the best treatment strategy, although surgical risk is not a predictor of 
MitraClip success or failure. Mitral valve surgery could be considered 
when concomitant CABG is required.14 In contrast, for severe FMR with LV 
dysfunction where no CABG is planned, MitraClip may be considered. 
Figure 2 shows a flowchart to guide the assessment and initial 
management of patients with ≥3+ FMR. 
Additionally, the panel outlined the technical considerations for the use of 
MitraClip in the treatment of DMR and FMR (Table 1). The MitraClip 
currently has a fourth-generation ‘G4’ device, which has been enhanced 
with an expanded range of four clip sizes (NTR, NTW, XTR, XTW), 
differentiated by clip arm length and width, independent leaflet grasping 
feature and real-time left atrial (LA) pressure monitoring capabilities.19,20 
The G4 system is already available in parts of Asia and these new features 
could aid in the treatment of challenging anatomies. 
Subgroups and Special Populations 
for MitraClip Use 
The use of the MitraClip was also considered in subgroups and special 
patient groups, including atrial FMR, concomitant MR/tricuspid 
regurgitation (TR), acute MR and hypertrophic obstructive cardiomyopathy 
(HOCM).
Statement 9. Patients with symptomatic atrial FMR should be 
evaluated by the Heart Team (including an electrophysiologist and 
heart failure specialist) and, if treatment has already been optimised, 
MitraClip may be considered.
Level of evidence: Low.
Level of agreement: 96% agree, 0% neutral, 4% disagree.
Although LA dilatation may occur in the absence of AF, a common cause 
of LA dilatation is long-standing AF.21 In patients with LA dilation due to AF, 
dilatation of the mitral annulus may lead to reduced leaflet coaptation and 
MR. Prominent LA dilation may cause posterior mitral leaflet tethering and 
restriction, which would result in atrial FMR.22 
One study compared the effect of MitraClip therapy in AF patients with 
atrial FMR (n=38) with those with ventricular FMR (n=49). In this study, 
atrial FMR was defined as MR with preserved LV function (LVEF ≥50%) and 
normal LV wall motion, while ventricular FMR was defined as MR with LV 
dysfunction (LVEF<50%) or LV wall motion abnormality. The study found 
that MitraClip was associated with an improvement of MR, with an 
increase in leaflet coaptation and a greater reduction of anteroposterior 
diameter and mitral annular area in patients with atrial FMR than in 
ventricular FMR.23 
Based on this study, the panel considered MitraClip a possible treatment 
option for symptomatic atrial FMR; hence, such patients should be 
evaluated by the Heart Team (including an electrophysiologist and heart 
failure specialist) for possible MitraClip implantation after other treatments 
have already been optimised. However, some panellists disagreed, 
pointing out that many patients with atrial FMR would be considered low 
risk for surgery, and maintained the role of surgical mitral valve repair in 
these patients. Nonetheless, for patients not amenable to surgery (e.g. 
some elderly patients), MitraClip is a reasonable option.
Lastly, it is worth noting that atrial FMR is often associated with severe 
TR24, which may limit the clinical benefit of transcatheter mitral intervention. 
Hence, this concomitant condition should also be assessed.
Statement 10. The expert panel acknowledges that MitraClip has 
been used in less common scenarios (e.g. acute MR, dynamic MR, 
HOCM, MR after failed surgical repair and TR) with reasonable 
reports of clinical success. However, enrolment into clinical trials or 
registries is preferred. Patients with these less common conditions 
should be evaluated by the Heart Team on a per-patient basis, with 
informed patient consent on the limited understanding available, to 
determine whether MitraClip use would be feasible and beneficial for 
them.
Level of evidence: Low.
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Case reports have documented the use of MitraClip in less common 
scenarios, such as acute MR, dynamic MR, HOCM, MR after failed surgical 
repair and TR, with reasonable reports of clinical success.25–32 
Table 1: Technical Considerations for 
MitraClip Use in Mitral Regurgitation
Ideal Complex Inappropriate
• Pathology in 
segment 2
• Valve area >4.0 cm2
• Pathology in segment 1 or 3
• Posterior leaflet length 
<7.0 mm
• Barlow’s syndrome
• Mitral valve cleft
• Severe calcification
• Prior annuloplasty
• Rheumatic leaflet thickening
• Leaflet perforation
• Active infective 
endocarditis
• Moderate-to-severe 
mitral stenosis (valve 
area ≤2.0 cm2)
• Left atrial thrombus
Level of agreement: 100% agree, 0% neutral, 0% disagree.
Figure 2: Flowchart for the Assessment and 
Initial Management of Patients With ≥3+ FMR
CRT-D = cardiac resynchronisation therapy defibrillator; FMR = functional mitral egurgitation; TOE = 
transoesophageal echocardiogram; TTE = transthoracic echocardiogram.
≥3+ FMR 
Refer to the Heart Team for MitraClip eligibility assessment 
• Coronary anatomy and ischaemia evaluation with revascularisation if appropriate
• Heart failure specialist to optimise medical therapy +/- CRT-D 
If persistent ≥3+ FMR: Re-evaluate by echocardiogram, preferably TOE for defining
aetiology and TTE for assessing severity 
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In the IREMMI trial, a multicentre registry that reported the feasibility of 
using MitraClip to treat acute MR in patients with acute myocardial 
infarction (n=93), patients had a procedural success rate of over 90% and 
a 30-day mortality rate of 6.5%.25
Another study, which included 221 patients who underwent MitraClip 
implantation, found that patients with dynamic severe MR experienced 
similar clinical improvement as patients with severe MR at rest, and that 
the majority of patients with dynamic severe MR experienced clinical 
improvement from NYHA functional class III/IV to I/II, as did those with 
severe MR at rest (59% versus 56%; p=0.566).26 
For TR, one study of 64 patients with severe TR on optimal medical 
treatment, who were unsuitable for surgery and so were treated with 
MitraClip implantation, found that TR was reduced by at least 1 grade in 
91% of the patients.31 Patients also had significant reductions in effective 
regurgitant orifice area (p<0.001), vena contracta width (p=0.001), and 
regurgitant volume (p<0.001). The 6-minute walking distance also 
increased significantly (p=0.007). A second observational study showed 
that in 50 patients, MitraClip treatment was associated with a 44% 
increase in 6-minute walk distance (p<0.001) and a non-significant 16% 
increase in quality-of-life scores (p=0.056).30 Despite these successes, 
clinicians should be aware that a separate catheter-based intervention 
(TriClip) has been evaluated in an international, prospective, single arm, 
multicentre study. This study, TRILUMINATE, found that in patients with 
moderate or greater TR, the TriClip reduced TR to moderate or less in 71% 
of patients (versus 8% at baseline; p<0.0001).33 Patients also experienced 
significant clinical improvements in NYHA functional class I/II (p<0.0001), 
6-minute walk test (p=0.0023) and Kansas City Cardiomyopathy 
Questionnaire score (p<0.0001).  
For HOCM, and MR after failed surgical repair, the current evidence has 
been limited to a few case reports.28,29,32 Beyond these reports, the use of 
MitraClip in these patients has not been evaluated in well-designed 
controlled trials so these patients should ideally be included in a clinical 
trial or patient registry. Should MitraClip be considered, patients with 
these less common conditions should be evaluated by the Heart Team on 
a per-patient basis, with informed patient consent on the limited 
understanding available, to determine whether MitraClip use would be 
feasible and beneficial for them. This opinion applies to patients who are 
not candidates for surgery, either due to surgical risk or due to lack of 
consent.
Conclusion
In all patients with MR, the aetiology, nature, and severity of the MR 
should be assessed, together with a thorough assessment of symptoms 
and overall surgical risk. Correctable underlying causes of MR should be 
adequately addressed together with the valvular problems. The 
determination of eligibility for MitraClip implantation requires a Heart 
Team approach to ensure a comprehensive benefit–risk assessment. 
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